154 related articles for article (PubMed ID: 34922058)
1. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
Dryden M; Kantecki M; Yan JL; Stone GG; Leister-Tebbe H; Wilcox M
J Glob Antimicrob Resist; 2022 Mar; 28():108-114. PubMed ID: 34922058
[TBL] [Abstract][Full Text] [Related]
2. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
Cheng K; Pypstra R; Yan JL; Hammond J
J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
[TBL] [Abstract][Full Text] [Related]
3. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
Wilcox M; Yan JL; Gonzalez PL; Dryden M; Stone GG; Kantecki M
Infect Dis Ther; 2022 Feb; 11(1):217-230. PubMed ID: 34741280
[TBL] [Abstract][Full Text] [Related]
4. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
5. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Scott LJ
Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
10. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Esposito S; Carrothers TJ; Riccobene T; Stone GG; Kantecki M
Paediatr Drugs; 2021 Nov; 23(6):549-563. PubMed ID: 34462863
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
14. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
Dryden M; Zhang Y; Wilson D; Iaconis JP; Gonzalez J
J Antimicrob Chemother; 2016 Dec; 71(12):3575-3584. PubMed ID: 27585969
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant
Torres A; Kuraieva A; Stone GG; Cillóniz C
Eur Respir Rev; 2023 Dec; 32(170):. PubMed ID: 37852658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.
Zhuo C; Huang Y; Liu W; Xu JF; Zhu WY; Stone GG; Yan JL; Mohamed N
Infect Drug Resist; 2022; 15():605-617. PubMed ID: 35237053
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
Li J; Das S; Zhou D; Al-Huniti N
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
